Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$15.39 - $22.1 $224,694 - $322,660
-14,600 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$16.16 - $20.66 $3.23 Million - $4.13 Million
-199,900 Reduced 93.19%
14,600 $2,000
Q2 2020

Aug 10, 2020

BUY
$13.31 - $19.41 $2.85 Million - $4.16 Million
214,500 New
214,500 $164,000
Q3 2018

Nov 09, 2018

SELL
$38.6 - $46.12 $3.91 Million - $4.67 Million
-101,200 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$40.56 - $51.36 $4.1 Million - $5.2 Million
101,200 New
101,200 $28,000
Q1 2018

May 11, 2018

SELL
$53.61 - $67.26 $814,872 - $1.02 Million
-15,200 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$47.69 - $55.39 $724,888 - $841,928
15,200
15,200 $93,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.84B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.